{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T18:19:37Z","timestamp":1759774777244,"version":"3.37.3"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"11-12","license":[{"start":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T00:00:00Z","timestamp":1649721600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T00:00:00Z","timestamp":1649721600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Sanofi-Genzyme"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Wien Klin Wochenschr"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1007\/s00508-022-02021-2","type":"journal-article","created":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T11:04:12Z","timestamp":1649761452000},"page":"471-477","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Long-term eliglustat treatment of Gaucher patients over up to 10\u00a0years in Vienna"],"prefix":"10.1007","volume":"134","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3300-6161","authenticated-orcid":false,"given":"Thomas M.","family":"Stulnig","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,4,12]]},"reference":[{"issue":"2","key":"2021_CR1","doi-asserted-by":"publisher","first-page":"441","DOI":"10.3390\/ijms18020441","volume":"18","author":"J Stirnemann","year":"2017","unstructured":"Stirnemann\u00a0J, Belmatoug\u00a0N, Camou\u00a0F, Serratrice\u00a0C, Froissart\u00a0R, Caillaud\u00a0C, et\u00a0al. A review of Gaucher disease pathophysiology, clinical presentation and treatments. Int J Mol Sci. 2017;18(2):441. https:\/\/doi.org\/10.3390\/ijms18020441.","journal-title":"Int J Mol Sci"},{"issue":"16","key":"2021_CR2","doi-asserted-by":"publisher","first-page":"e118","DOI":"10.1182\/blood-2011-05-352971","volume":"118","author":"N Dekker","year":"2011","unstructured":"Dekker\u00a0N, van Dussen\u00a0L, Hollak\u00a0CE, Overkleeft\u00a0H, Scheij\u00a0S, Ghauharali\u00a0K, et\u00a0al. Elevated plasma glucosylsphingosine in Gaucher disease: relation to phenotype, storage cell markers, and therapeutic response. Blood. 2011;118(16):e118\u2013e27. https:\/\/doi.org\/10.1182\/blood-2011-05-352971.","journal-title":"Blood"},{"issue":"4","key":"2021_CR3","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/S0950-3536(97)80033-9","volume":"10","author":"TM Cox","year":"1997","unstructured":"Cox\u00a0TM, Schofield\u00a0JP. Gaucher\u2019s disease: clinical features and natural history. Baillieres Clin Haematol. 1997;10(4):657\u201389.","journal-title":"Baillieres Clin Haematol"},{"issue":"4","key":"2021_CR4","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1111\/bjh.12804","volume":"165","author":"AS Thomas","year":"2014","unstructured":"Thomas\u00a0AS, Mehta\u00a0A, Hughes\u00a0DA. Gaucher disease: haematological presentations and complications. Br J Haematol. 2014;165(4):427\u201340. https:\/\/doi.org\/10.1111\/bjh.12804.","journal-title":"Br J Haematol"},{"issue":"2","key":"2021_CR5","first-page":"127","volume":"49","author":"J P\u00e9rez-Calvo","year":"2003","unstructured":"P\u00e9rez-Calvo\u00a0J, Giraldo\u00a0P, Pastores\u00a0GM, Fern\u00e1ndez-Gal\u00e1n\u00a0M, Mart\u00edn-Nu\u00f1ez\u00a0G, Pocov\u00ed\u00a0M. Extended interval between enzyme therapy infusions for adult patients with Gaucher\u2019s disease type 1. J\u00a0Postgrad Med. 2003;49(2):127\u201331.","journal-title":"J Postgrad Med"},{"key":"2021_CR6","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s13023-016-0413-3","volume":"11","author":"BE Smid","year":"2016","unstructured":"Smid\u00a0BE, Ferraz\u00a0MJ, Verhoek\u00a0M, Mirzaian\u00a0M, Wisse\u00a0P, Overkleeft\u00a0HS, et\u00a0al. Biochemical response to substrate reduction therapy versus enzyme replacement therapy in Gaucher disease type 1\u00a0patients. Orphanet J Rare Dis. 2016;11:28. https:\/\/doi.org\/10.1186\/s13023-016-0413-3.","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"2021_CR7","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1002\/ajh.20504","volume":"80","author":"NJ Weinreb","year":"2005","unstructured":"Weinreb\u00a0NJ, Barranger\u00a0JA, Charrow\u00a0J, Grabowski\u00a0GA, Mankin\u00a0HJ, Mistry\u00a0P. Guidance on the use of miglustat for treating patients with type 1 Gaucher disease. Am J Hematol. 2005;80(3):223\u20139. https:\/\/doi.org\/10.1002\/ajh.20504.","journal-title":"Am J Hematol"},{"issue":"6","key":"2021_CR8","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1182\/blood-2010-03-273151","volume":"116","author":"E Lukina","year":"2010","unstructured":"Lukina\u00a0E, Watman\u00a0N, Arreguin\u00a0EA, Banikazemi\u00a0M, Dragosky\u00a0M, Iastrebner\u00a0M, et al. A phase 2\u00a0study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1. Blood. 2010;116(6):893\u20139. https:\/\/doi.org\/10.1182\/blood-2010-03-273151.","journal-title":"Blood"},{"issue":"7","key":"2021_CR9","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1001\/jama.2015.459","volume":"313","author":"PK Mistry","year":"2015","unstructured":"Mistry\u00a0PK, Lukina\u00a0E, Ben Turkia\u00a0H, Amato\u00a0D, Baris\u00a0H, Dasouki\u00a0M, et\u00a0al. Effect of oral eliglustat on splenomegaly in patients with Gaucher disease type 1: the ENGAGE randomized clinical trial. JAMA. 2015;313(7):695\u2013706. https:\/\/doi.org\/10.1001\/jama.2015.459.","journal-title":"JAMA"},{"issue":"9985","key":"2021_CR10","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1016\/S0140-6736(14)61841-9","volume":"385","author":"TM Cox","year":"2015","unstructured":"Cox\u00a0TM, Drelichman\u00a0G, Cravo\u00a0R, Balwani\u00a0M, Burrow\u00a0TA, Martins\u00a0AM, et al. Eliglustat compared with imiglucerase in patients with Gaucher\u2019s disease type 1 stabilised on enzyme replacement therapy: a\u00a0phase 3, randomised, open-label, non-inferiority trial. Lancet. 2015;385(9985):2355\u201362. https:\/\/doi.org\/10.1016\/S0140-6736(14)61841-9.","journal-title":"Lancet"},{"issue":"3","key":"2021_CR11","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.ymgme.2017.12.001","volume":"123","author":"J Charrow","year":"2018","unstructured":"Charrow\u00a0J, Fraga\u00a0C, Gu\u00a0X, Ida\u00a0H, Longo\u00a0N, Lukina\u00a0E, et al. Once- versus twice-daily dosing of eliglustat in adults with Gaucher disease type 1: the phase 3, randomized, double-blind EDGE trial. Mol Genet Metab. 2018;123(3):347\u201356. https:\/\/doi.org\/10.1016\/j.ymgme.2017.12.001.","journal-title":"Mol Genet Metab"},{"key":"2021_CR12","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ejim.2016.07.011","volume":"37","author":"N Belmatoug","year":"2017","unstructured":"Belmatoug\u00a0N, Di Rocco\u00a0M, Fraga\u00a0C, Giraldo\u00a0P, Hughes\u00a0D, Lukina\u00a0E, et\u00a0al. Management and monitoring recommendations for the use of eliglustat in adults with type 1 Gaucher disease in Europe. Eur J Intern Med. 2017;37:25\u201332. https:\/\/doi.org\/10.1016\/j.ejim.2016.07.011.","journal-title":"Eur J Intern Med"},{"key":"2021_CR13","doi-asserted-by":"publisher","first-page":"100614","DOI":"10.1016\/j.ymgmr.2020.100614","volume":"24","author":"E Dimitriou","year":"2020","unstructured":"Dimitriou\u00a0E, Moraitou\u00a0M, Cozar\u00a0M, Serra-Vinardell\u00a0J, Vilageliu\u00a0L, Grinberg\u00a0D, et al. Gaucher disease: Biochemical and molecular findings in 141\u00a0patients diagnosed in Greece. Mol Genet Metab Rep. 2020;24:100614. https:\/\/doi.org\/10.1016\/j.ymgmr.2020.100614.","journal-title":"Mol Genet Metab Rep"},{"issue":"9","key":"2021_CR14","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1002\/ajh.25875","volume":"95","author":"PK Mistry","year":"2020","unstructured":"Mistry\u00a0PK, Balwani\u00a0M, Charrow\u00a0J, Kishnani\u00a0P, Niederau\u00a0C, Underhill\u00a0LH, et al. Real-world effectiveness of eliglustat in treatment-naive and switch patients enrolled in the International Collaborative Gaucher Group Gaucher Registry. Am J Hematol. 2020;95(9):1038\u201346. https:\/\/doi.org\/10.1002\/ajh.25875.","journal-title":"Am J Hematol"},{"issue":"7","key":"2021_CR15","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1002\/psp4.12506","volume":"9","author":"R Abrams","year":"2020","unstructured":"Abrams\u00a0R, Kaddi\u00a0CD, Tao\u00a0M, Leiser\u00a0RJ, Simoni\u00a0G, Reali\u00a0F, et\u00a0al. A quantitative systems pharmacology model of Gaucher disease type 1 provides mechanistic insight into the response to substrate reduction therapy with eliglustat. CPT Pharmacometrics Syst Pharmacol. 2020;9(7):374\u201383. https:\/\/doi.org\/10.1002\/psp4.12506.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"9","key":"2021_CR16","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1002\/ajh.26276","volume":"96","author":"PK Mistry","year":"2021","unstructured":"Mistry\u00a0PK, Lukina\u00a0E, Ben Turkia\u00a0H, Shankar\u00a0SP, Baris Feldman\u00a0H, Ghosn\u00a0M, et\u00a0al. Clinical outcomes after 4.5\u00a0years of eliglustat therapy for Gaucher disease type 1: phase 3 ENGAGE trial final results. Am J Hematol. 2021;96(9):1156\u201365. https:\/\/doi.org\/10.1002\/ajh.26276.","journal-title":"Am J Hematol"},{"key":"2021_CR17","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ymgmr.2016.06.003","volume":"8","author":"J Ibrahim","year":"2016","unstructured":"Ibrahim\u00a0J, Underhill\u00a0LH, Taylor\u00a0JS, Angell\u00a0J, Peterschmitt\u00a0MJ. Clinical response to eliglustat in treatment-naive patients with Gaucher disease type 1: post-hoc comparison to imiglucerase-treated patients enrolled in the International Collaborative Gaucher Group Gaucher Registry. Mol Genet Metab Rep. 2016;8:17\u20139. https:\/\/doi.org\/10.1016\/j.ymgmr.2016.06.003.","journal-title":"Mol Genet Metab Rep"},{"issue":"1","key":"2021_CR18","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1002\/jmd2.12172","volume":"57","author":"E Lukina","year":"2021","unstructured":"Lukina\u00a0E, Balwani\u00a0M, Belmatoug\u00a0N, Watman\u00a0N, Hughes\u00a0D, Gaemers\u00a0SJM, et\u00a0al. Pregnancy outcome in women with Gaucher disease type 1 who had unplanned pregnancies during eliglustat clinical trials. JIMD Rep. 2021;57(1):76\u201384. https:\/\/doi.org\/10.1002\/jmd2.12172.","journal-title":"JIMD Rep"},{"issue":"17","key":"2021_CR19","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-12-758409","volume":"129","author":"TM Cox","year":"2017","unstructured":"Cox\u00a0TM, Drelichman\u00a0G, Cravo\u00a0R, Balwani\u00a0M, Burrow\u00a0TA, Martins\u00a0AM, et al. Eliglustat maintains long-term clinical stability in patients with Gaucher disease type 1 stabilized on enzyme therapy. Blood. 2017;129(17):2375\u201383. https:\/\/doi.org\/10.1182\/blood-2016-12-758409.","journal-title":"Blood"},{"issue":"1","key":"2021_CR20","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1002\/ajh.25300","volume":"94","author":"E Lukina","year":"2019","unstructured":"Lukina\u00a0E, Watman\u00a0N, Dragosky\u00a0M, Lau\u00a0H, Avila Arreguin\u00a0E, Rosenbaum\u00a0H, et\u00a0al. Outcomes after 8\u00a0years of eliglustat therapy for Gaucher disease type 1: final results from the phase 2 trial. Am J Hematol. 2019;94(1):29\u201338. https:\/\/doi.org\/10.1002\/ajh.25300.","journal-title":"Am J Hematol"},{"key":"2021_CR21","doi-asserted-by":"publisher","first-page":"100606","DOI":"10.1016\/j.ymgmr.2020.100606","volume":"24","author":"K Sidhu","year":"2020","unstructured":"Sidhu\u00a0K, Boyd\u00a0SK, Khan\u00a0A. Impact on bone microarchitecture and failure load in a\u00a0patient with type I Gaucher disease who switched from Imiglucerase to eliglustat. Mol Genet Metab Rep. 2020;24:100606. https:\/\/doi.org\/10.1016\/j.ymgmr.2020.100606.","journal-title":"Mol Genet Metab Rep"},{"issue":"1","key":"2021_CR22","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s13023-019-1085-6","volume":"14","author":"MJ Peterschmitt","year":"2019","unstructured":"Peterschmitt\u00a0MJ, Freisens\u00a0S, Underhill\u00a0LH, Foster\u00a0MC, Lewis\u00a0G, Gaemers\u00a0SJM. Long-term adverse event profile from four completed trials of oral eliglustat in adults with Gaucher disease type 1. Orphanet J Rare Dis. 2019;14(1):128. https:\/\/doi.org\/10.1186\/s13023-019-1085-6.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"2021_CR23","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s12881-017-0403-x","volume":"18","author":"YM Kim","year":"2017","unstructured":"Kim\u00a0YM, Shin\u00a0DH, Park\u00a0SB, Cheon\u00a0CK, Yoo\u00a0HW. Case report of unexpected gastrointestinal involvement in type 1 Gaucher disease: comparison of eliglustat tartrate treatment and enzyme replacement therapy. BMC Med Genet. 2017;18(1):55. https:\/\/doi.org\/10.1186\/s12881-017-0403-x.","journal-title":"BMC Med Genet"}],"container-title":["Wiener klinische Wochenschrift"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-022-02021-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00508-022-02021-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-022-02021-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T12:30:52Z","timestamp":1655814652000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00508-022-02021-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,12]]},"references-count":23,"journal-issue":{"issue":"11-12","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["2021"],"URL":"https:\/\/doi.org\/10.1007\/s00508-022-02021-2","relation":{},"ISSN":["0043-5325","1613-7671"],"issn-type":[{"type":"print","value":"0043-5325"},{"type":"electronic","value":"1613-7671"}],"subject":[],"published":{"date-parts":[[2022,4,12]]},"assertion":[{"value":"13 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"T.M.\u00a0Stulnig received travel and research support as well as honoraria from Sanofi and Shire\/Takeda. The publication of this manuscript was supported by Sanofi.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}